ライフサイエンスコーパス: critical limb ischemia

1 a-initiated blood flow recovery resulting in critical limb ischemia.

2 an increased odds of death in patients with critical limb ischemia.

3 sions, is an effective primary treatment for critical limb ischemia.

4 eutic angiogenesis in selected patients with critical limb ischemia.

5 ential therapeutic benefits in patients with critical limb ischemia.

6 pathophysiology, diagnosis, and treatment of critical limb ischemia.

7 e treatment of peripheral artery disease and critical limb ischemia.

8 s are positively correlated in patients with critical limb ischemia.

9 ise performance and the potential to develop critical limb ischemia.

10 a key role in the treatment of patients with critical limb ischemia.

11 he most severe manifestation of the disease, critical limb ischemia.

12 to reduce amputation rates among those with critical limb ischemia.

13 ion is upregulated in patients and mice with critical limb ischemia.

14 n patients with symptomatic claudication and critical limb ischemia.

15 pond to medical management and patients with critical limb ischemia.

16 n were older and have multilevel disease and critical limb ischemia.

17 te limb ischemia or an acute exacerbation of critical limb ischemia.

18 to modify the natural history of intractable critical limb ischemia.

19 from T2DM patients undergoing amputation for critical limb ischemia.

20 w-the-knee lesions in diabetic patients with critical limb ischemia.

21 ese acute presentations were attributable to critical limb ischemia.

22 rarefaction, especially when associated with critical limb ischemia.

23 k wave alone in improving ischemia in rodent critical limb ischemia.

24 for intractable peripheral arterial disease/critical limb ischemia.

25 therapeutic target in diabetic patients with critical limb ischemia.

26 therapeutic utility in elderly patients with critical limb ischemia.

27 amputations in patients with below-the-knee critical limb ischemia.

28 bleeding in patients undergoing surgery for critical limb ischemia.

29 the patients had claudication, and 4.6% had critical limb ischemia.

30 e form of HIF-1alpha, in a diabetic model of critical limb ischemia.

31 treatment for peripheral artery disease and critical limb ischemia.

32 /-2.4% and 8.3+/-3.1%, log-rank P<0.001) and critical limb ischemia (19.1+/-4.8% and 31.6+/-6.3% at 1

33 ompared with acute limb ischemia (75.3%) and critical limb ischemia (92.6%; P<0.001).

34 Critical limb ischemia, a manifestation of severe periph

35 a on the incidence and long-term outcomes of critical limb ischemia, acute limb ischemia, or acute vi

36 dence interval, 1.69-5.35), particularly for critical limb ischemia (adjusted risk ratio, 5.96; 95% c

37 ons, poor distal runoff, and the presence of critical limb ischemia all have contributed to the disap

38 In contrast, critical limb ischemia and acute limb ischemia threaten

39 dred twenty-five limbs (of 89 patients) with critical limb ischemia and ankle brachial index >/=1.4 w

40 lation of S100A1 expression in patients with critical limb ischemia and identifies S100A1 as critical

41 transplanted in patients with myocardial and critical limb ischemia and in animal models.

42 Conclusions and Relevance: Understanding critical limb ischemia and its treatment strategies is i

43 Among patients with critical limb ischemia and noncompressible ankle brachia

44 s with end-stage vascular disease, including critical limb ischemia and refractory myocardial ischemi

45 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia.

46 n graft operations performed exclusively for critical limb ischemia at 83 North American centers.

47 ersus Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI) study is a randomized

48 In patients with critical limb ischemia caused by infrapopliteal lesions,

49 intermittent claudication (IC) (n = 23) and critical limb ischemia (CLI) (n = 23).

50 Critical limb ischemia (CLI) continues to be a major cau

51 ients (claudication 101 patients (36.7%) and critical limb ischemia (CLI) in 174 patients (63.3%).

52 Critical limb ischemia (CLI) is a clinical syndrome of i

53 Critical Limb Ischemia (CLI) is the most advanced stage

54 impact of severe cardiovascular disease and critical limb ischemia (CLI) on the bone marrow (BM) is

55 raight inline arterial flow in patients with critical limb ischemia (CLI) or lifestyle-limiting claud

56 of tibioperoneal vessel angioplasty (TPVA), critical limb ischemia (CLI) patients' data were analyze

57 constitute a major health care burden among critical limb ischemia (CLI) patients.

58 ents (MACCE) and amputation-free survival in critical limb ischemia (CLI) patients.

59 : (1) to profile miR expression in PACs from critical limb ischemia (CLI) patients; (2) to demonstrat

60 ural vascular care obtained by patients with critical limb ischemia (CLI) remains unknown.

61 ients are hospitalized for the management of critical limb ischemia (CLI), but limited data are avail

62 Critical limb ischemia (CLI), foot ulcers, former amputa

63 Critical limb ischemia (CLI), the most advanced form of

64 laudication, that is, pain with walking, and critical limb ischemia (CLI), which includes pain at res

65 m cells (MSC) are promising therapeutics for critical limb ischemia (CLI).

66 ascularization improvements in patients with critical limb ischemia (CLI).

67 oss of injected stem cells in PIRI including critical limb ischemia (CLI).

68 arterial revascularization in patients with critical limb ischemia (CLI).

69 been successfully used for the treatment of critical limb ischemia (CLI).

70 us oxygen tension (TcPo(2)) in patients with critical limb ischemia (CLI).

71 y showed scarcity of BM PCs in T2DM and T2DM+critical limb ischemia compared with C, but similar leve

72 Black patients with critical limb ischemia face significantly higher risk of

73 Patients with critical limb ischemia had the highest TAC scores, and i

74 Patients with critical limb ischemia have a perioperative cardiovascul

75 undergoing ankle brachial index testing for critical limb ischemia have noncompressible vessels beca

76 Most patients with critical limb ischemia have severe below-the-knee arteri

77 d to Improve Limb Perfusion in Patients With Critical Limb Ischemia (HGF-STAT trial) determined the e

78 Bone marrow cell (BMC)-based treatment for critical limb ischemia in diabetic patients yielded a mo

79 novel avenues for cell-based therapeutics of critical limb ischemia in diabetic patients.

80 ells might exert enhanced protection against critical limb ischemia in rats.

81 enitor cell-extracorporeal shock wave) after critical limb ischemia induction.

82 RATIONALE: Critical limb ischemia is a life-threatening complicatio

83 Critical limb ischemia is a manifestation of peripheral

84 Critical limb ischemia is characterized by rest pain and

85 is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smokin

86 use completely, amputation will not occur if critical limb ischemia is not already present.

87 les were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or

88 Importance: Chronic critical limb ischemia, marked by intractable lower extr

89 Critical limb ischemia patients have a 1-year amputation

90 rdiovascular risk and prevent progression to critical limb ischemia, patients with PAD continue to be

91 In patients with critical limb ischemia, perioperative dual antiplatelet

92 Critical limb ischemia portends a risk of major amputati

93 In total, 34 no-option patients with critical limb ischemia received HIF-1alpha at doses of 1

94 sis >50%, retreatment, major amputation, and critical limb ischemia-related death were regarded as tr

95 Findings: Critical limb ischemia represents the end stage of perip

96 In its most severe form, critical limb ischemia, rest pain, and tissue necrosis a

97 ilure of vein bypass grafts in patients with critical limb ischemia results in morbidity, limb loss,

98 Adults with critical limb ischemia (Rutherford category >/=4) and in

99 Inclusion criteria were diabetes mellitus, critical limb ischemia (Rutherford class 4 or higher), s

100 and limb salvage in patients presenting with critical limb ischemia; secondary aims include (1) cost-

101 Patients with chronic critical limb ischemia showed almost complete loss of S1

102 Twenty-eight critical limb ischemia subjects were randomized and trea

103 For patients with critical limb ischemia, the goals of revascularization a

104 dures because of acute coronary syndromes or critical limb ischemia, the outcomes are less favorable

105 findings link its pathological plasticity in critical limb ischemia to impaired neovascularization, p

106 ivided into group 1 (sham control), group 2 (critical limb ischemia treated with culture medium), gro

107 progenitor cells [2.0 x 10 cells]), group 4 (critical limb ischemia treated with extracorporeal shock

108 hemia treated with culture medium), group 3 (critical limb ischemia treated with intramuscular bone m

109 tion of restenosis in diabetic patients with critical limb ischemia undergoing endovascular intervent

110 ar infrapopliteal treatment of patients with critical limb ischemia using percutaneous transluminal a

111 HIF-1alpha therapy in patients with critical limb ischemia was well tolerated, supporting fu

112 Here, in a preclinical model of critical limb ischemia, we assessed a novel method of ce

113 inguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg

114 cells in subjects with moderate or high-risk critical limb ischemia, who were poor or noncandidates f

115 Treating below-the-knee critical limb ischemia with DES is an effective and safe

116 a) into the lower extremity of patients with critical limb ischemia would be safe and might result in